GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...

UK pharma group posts ‘statistically significant’ trial results for treatment combined with Blenrep pulled in 2022 ...

GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects a multi-blockbuster ...

GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an ...

The FTSE 100 has pulled back with the government’s policy choices creating some negative sentiment. But this gives us a ...

GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...

GSK's phase 3 trial shows Blenrep combined with BorDex improves overall survival in relapsed multiple myeloma.

For the past three years, biotechs and pharmas have renamed, rebranded and more in a bid to refresh their corporate appeal. ...

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

Reporters @statnews asked leaders in the life sciences commuity for reactions to RFK Jr.'s selection as health secretary. Many were aghast, while others played down the news.

Shares of vaccine makers closed lower Thursday amid reports that President-elect Donald Trump was set to nominate vaccine ...

As federal health scientists await a potential takeover by RFK Jr. and other medical skeptics in the second Trump ...